{"entity":{"id":"nct07387081","kind":"trial","name":"Phase II Study of LM-24C5","aka":[],"tldr":"A phase 2 trial of LM-24C5 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","summary":"Phase II Study of LM-24C5 is a phase 2 interventional study registered as NCT07387081 by LaNova Medicines Limited, with 130 participants planned, started 2025-12-15 and due to reach its primary completion in 2028-05-21. Interventions recorded: LM-24C5.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07387081","url":"https://clinicaltrials.gov/study/NCT07387081"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lanova-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07387081","phase":"2","setting":"An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of LM-24C5 in Combination With Other Anti-tumor Treatment in Subjects With CEACAM5-positive Advanced Solid Tumors","sponsor":"LaNova Medicines Limited","enrolled":130,"outcomes":[]},"route":"/trials/nct07387081/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"}]}}